Urcosimod Progresses to Global Phase 3 Trial for Non-Infectious Uveitis After FDA Nod

OKYO Pharma's drug candidate, urcosimod, has received clearance from the U.S. FDA to advance into a global Phase 3 clinical trial. This development is significant for non-infectious uveitis, a condition that currently lacks an FDA-approved treatment. The progression of urcosimod offers hope for patients seeking effective therapy for this eye inflammation.